BEAT (HeartBeam) Short Interest

View and export this data going back to 2021. Start your Free Trial

What is HeartBeam Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of HeartBeam's Short Interest

For the Health Information Services subindustry, HeartBeam's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HeartBeam's Short Interest Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, HeartBeam's Short Interest distribution charts can be found below:

* The bar in red indicates where HeartBeam's Short Interest falls into.

Save Embed

;

Save Embed

;

HeartBeam Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » HeartBeam Inc (NAS:BEAT) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

2118 Walsh Avenue, Suite 210, Santa Clara, CA, USA, 95050

Website

https://www.heartbeam.com

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Executives

Richard M Ferrari	director, officer: Exec Chm of the BOD	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Urioste George De	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Kenneth Harry Persen	officer: Chief Technology Officer	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Robert Paul Eno	officer: President	2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Michael R Jaff	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Mark E Strome	10 percent owner	100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Nelson Kenneth Warwick Iii	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Richard D Brounstein	officer: Chief Financial Officer	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Alan Baumel	officer: Chief Operating Officer	2118 WALSH AVE, SUITE 210, SANTA CLARA CA 94050
Marga Ortigas-wedekind	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Branislav Vajdic	10 percent owner, officer: Chief Executive Officer	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Willhem Elfrink	director	2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050
Jon Patrick Hunt	officer: Chief Business Officer	2118 WALSH AVE, SUITE 210, SANTA CLARA CA 95050